Most Read Articles
6 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Roshini Claire Anthony, 5 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

07 Jun 2019
Low-dose aspirin therapy does not confer significant benefits to elderly patients with hypertension, but treatment appears to increase the risk of haemorrhagic events, suggest a Japan study.
5 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.

Stage 1 hypertension strongly predicts 10-year CVD events

19 May 2019

Stage 1 hypertension but not elevated blood pressure (BP) appears to be associated with a significant increase in the incidence of fatal and nonfatal cardiovascular disease (CVD) events over a 10-year follow-up, according to data from the ATTICA study.

The analysis involved 3,042 randomly selected Greek adults aged 18–89 years. Hypertension status was defined based on mean systolic/diastolic blood pressure and the most recent 2017 ACC/AHA guidelines: high normal blood pressure (HNBP; systolic, 120–139 mm Hg; diastolic, 80–89 mm Hg; no prior history of high blood pressure), elevated BP (systolic, 120–129 mm Hg; diastolic, <80 mm Hg) and stage 1 hypertension (systolic, 130–139 mm Hg; diastolic, 80–89 mm Hg).

In the cohort, the prevalence rates of HNBP, elevated BP and stage 1 hypertension were 44.6 percent (n=626), 29.0 percent (n=408) and 15.5 percent (n=218), respectively.

Incident fatal and nonfatal CVD events during follow-up of 10 years occurred in 98 patients (15.6 percent) in the HNBP group, 49 (12.0 percent) in the elevated BP group and 49 (22.5 percent) in the stage 1 hypertension group as compared with 49 (6.3 percent) in the normotension group (p<0.0001 for all).

Relative to normal BP, HNBP and stage 1 hypertension contributed to an increased risk of 10-year CVD. The risk increased by 1.5-fold with HNBP (adjusted hazard ratio [aHR], 1.49; 95 percent CI, 1.00–2.20) and by twofold with stage 1 hypertension (aHR, 1.90; 1.16–3.08). The risk increase was particularly pronounced in males (aHR, 2.03; 1.08–3.83).

On the other hand, elevated BP was not associated with an increased risk of developing 10-year CVD events (aHR, 1.28; 0.82–2.02).

In light of a notable increased risk of 10-year fatal and nonfatal CVD events associated with HNBP and stage 1 hypertension, researchers called for the implementation of targeted primary and secondary prevention interventions that may deter both CVD and related adverse health outcomes.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Roshini Claire Anthony, 5 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

07 Jun 2019
Low-dose aspirin therapy does not confer significant benefits to elderly patients with hypertension, but treatment appears to increase the risk of haemorrhagic events, suggest a Japan study.
5 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.